176 related articles for article (PubMed ID: 19364838)
1. Expression of B-cell activating factor enhances protective immunity of a vaccine against Pseudomonas aeruginosa.
Tertilt C; Joh J; Krause A; Chou P; Schneeweiss K; Crystal RG; Worgall S
Infect Immun; 2009 Jul; 77(7):3044-55. PubMed ID: 19364838
[TBL] [Abstract][Full Text] [Related]
2. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
Front Immunol; 2019; 10():2497. PubMed ID: 31708925
[No Abstract] [Full Text] [Related]
3. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.
Krause A; Whu WZ; Xu Y; Joh J; Crystal RG; Worgall S
Vaccine; 2011 Mar; 29(11):2131-9. PubMed ID: 21215829
[TBL] [Abstract][Full Text] [Related]
4. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
Kamei A; Coutinho-Sledge YS; Goldberg JB; Priebe GP; Pier GB
Infect Immun; 2011 Mar; 79(3):1289-99. PubMed ID: 21149583
[TBL] [Abstract][Full Text] [Related]
5. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
[TBL] [Abstract][Full Text] [Related]
6. RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF.
Krause A; Whu WZ; Qiu J; Wafadari D; Hackett NR; Sharma A; Crystal RG; Worgall S
Clin Exp Immunol; 2013 Aug; 173(2):230-41. PubMed ID: 23607394
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.
Campodónico VL; Llosa NJ; Bentancor LV; Maira-Litran T; Pier GB
Infect Immun; 2011 Aug; 79(8):3455-64. PubMed ID: 21628521
[TBL] [Abstract][Full Text] [Related]
8. Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity.
Heurtault B; Gentine P; Thomann JS; Baehr C; Frisch B; Pons F
Pharm Res; 2009 Feb; 26(2):276-85. PubMed ID: 18781377
[TBL] [Abstract][Full Text] [Related]
9. IL17-Producing γδ T Cells May Enhance Humoral Immunity during Pulmonary
Pan T; Tan R; Li M; Liu Z; Wang X; Tian L; Liu J; Qu H
Front Cell Infect Microbiol; 2016; 6():170. PubMed ID: 27999768
[TBL] [Abstract][Full Text] [Related]
10. Defining the Mechanistic Correlates of Protection Conferred by Whole-Cell Vaccination against Pseudomonas aeruginosa Acute Murine Pneumonia.
Sen-Kilic E; Blackwood CB; Huckaby AB; Horspool AM; Weaver KL; Malkowski AC; Witt WT; Bevere JR; Damron FH; Barbier M
Infect Immun; 2021 Jan; 89(2):. PubMed ID: 33199354
[No Abstract] [Full Text] [Related]
11. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
Hamaoka S; Naito Y; Katoh H; Shimizu M; Kinoshita M; Akiyama K; Kainuma A; Moriyama K; Ishii KJ; Sawa T
Microbiol Immunol; 2017 Feb; 61(2):64-74. PubMed ID: 28370521
[TBL] [Abstract][Full Text] [Related]
12. Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.
Meynet E; Laurin D; Lenormand JL; Camara B; Toussaint B; Le Gouëllec A
Vaccine; 2018 Mar; 36(14):1893-1900. PubMed ID: 29506924
[TBL] [Abstract][Full Text] [Related]
13. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.
Wu W; Huang J; Duan B; Traficante DC; Hong H; Risech M; Lory S; Priebe GP
Am J Respir Crit Care Med; 2012 Sep; 186(5):420-7. PubMed ID: 22723292
[TBL] [Abstract][Full Text] [Related]
14. Increased Immunogenicity and Protective Efficacy of a
Ryu JI; Wui SR; Ko A; Lee YJ; Do H; Kim HJ; Rhee IM; Park SA; Kim KS; Cho YJ; Lee NG
J Microbiol Biotechnol; 2017 Aug; 27(8):1539-1548. PubMed ID: 28621112
[No Abstract] [Full Text] [Related]
15. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous
Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W
Front Immunol; 2018; 9():1737. PubMed ID: 30093906
[No Abstract] [Full Text] [Related]
16. Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF.
Worgall S; Krause A; Qiu J; Joh J; Hackett NR; Crystal RG
J Virol; 2007 Dec; 81(24):13801-8. PubMed ID: 17942539
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of pilin protein with alum+naloxone adjuvant against acute pulmonary Pseudomonas aeruginosa infection.
Banadkoki AZ; Keshavarzmehr M; Afshar Z; Aleyasin N; Fatemi MJ; Behrouz B; Hashemi FB
Biologicals; 2016 Sep; 44(5):367-73. PubMed ID: 27427517
[TBL] [Abstract][Full Text] [Related]
18. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
[TBL] [Abstract][Full Text] [Related]
19. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
[TBL] [Abstract][Full Text] [Related]
20. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
